These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 20520852)

  • 21. Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor.
    Grant MK; Noetzel MJ; De Lorme KC; Jakubík J; Doležal V; El-Fakahany EE
    PLoS One; 2010 Dec; 5(12):e15722. PubMed ID: 21203415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting muscarinic receptors to treat schizophrenia.
    Foster DJ; Bryant ZK; Conn PJ
    Behav Brain Res; 2021 May; 405():113201. PubMed ID: 33647377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
    Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
    N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain.
    Machová E; Jakubík J; El-Fakahany EE; Dolezal V
    J Pharmacol Exp Ther; 2007 Jul; 322(1):316-23. PubMed ID: 17446301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
    Teal LB; Gould RW; Felts AS; Jones CK
    Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.
    Dean B
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
    Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM
    Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biased Profile of Xanomeline at the Recombinant Human M
    McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C
    ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.
    Jones CK; Brady AE; Davis AA; Xiang Z; Bubser M; Tantawy MN; Kane AS; Bridges TM; Kennedy JP; Bradley SR; Peterson TE; Ansari MS; Baldwin RM; Kessler RM; Deutch AY; Lah JJ; Levey AI; Lindsley CW; Conn PJ
    J Neurosci; 2008 Oct; 28(41):10422-33. PubMed ID: 18842902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.
    Conn PJ; Jones CK; Lindsley CW
    Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors.
    Shannon HE; Bymaster FP; Calligaro DO; Greenwood B; Mitch CH; Sawyer BD; Ward JS; Wong DT; Olesen PH; Sheardown MJ; Swedberg MD; Suzdak PD; Sauerberg P
    J Pharmacol Exp Ther; 1994 Apr; 269(1):271-81. PubMed ID: 7909557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors.
    Croy CH; Schober DA; Xiao H; Quets A; Christopoulos A; Felder CC
    Mol Pharmacol; 2014 Jul; 86(1):106-15. PubMed ID: 24807965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classical and atypical agonists activate M1 muscarinic acetylcholine receptors through common mechanisms.
    Randáková A; Dolejší E; Rudajev V; Zimčík P; Doležal V; El-Fakahany EE; Jakubík J
    Pharmacol Res; 2015 Jul; 97():27-39. PubMed ID: 25882246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.
    Jakubík J; El-Fakahany EE; Dolezal V
    Mol Pharmacol; 2006 Aug; 70(2):656-66. PubMed ID: 16675658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.
    De Lorme KC; Grant MK; Noetzel MJ; Polson SB; El-Fakahany EE
    J Pharmacol Exp Ther; 2007 Dec; 323(3):868-76. PubMed ID: 17855477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.
    Yohn SE; Weiden PJ; Felder CC; Stahl SM
    Trends Pharmacol Sci; 2022 Dec; 43(12):1098-1112. PubMed ID: 36273943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.
    Azargoonjahromi A
    Clin Drug Investig; 2024 Jul; 44(7):471-493. PubMed ID: 38904739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
    Stengel PW; Cohen ML
    J Pharmacol Exp Ther; 2001 Mar; 296(3):818-24. PubMed ID: 11181912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.
    Suratman S; Leach K; Sexton P; Felder C; Loiacono R; Christopoulos A
    Br J Pharmacol; 2011 Apr; 162(7):1659-70. PubMed ID: 21198541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.
    Chan WY; McKinzie DL; Bose S; Mitchell SN; Witkin JM; Thompson RC; Christopoulos A; Lazareno S; Birdsall NJ; Bymaster FP; Felder CC
    Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10978-83. PubMed ID: 18678919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.